Document is current
Any future updates will be listed below
-
Authors
Collin, Lindsay J.
Woolpert, Kirsten M.
Kjaersgaard, Anders
Ahern, Thomas P.
Goodman, Michael
McCullough, Lauren E.
Waller, Lance A.
Christensen, Kristina B.
Damkier, Per
Hamilton-Dutoit, Stephen J.
Lauridsen, Kristina L.
Christiansen, Peer M.
Ejlertsen, Bent
Sørensen, Henrik T.
Cronin-Fenton, Deirdre P.
Lash, Timothy L.
-
Funding
Funding for this research was provided by:
National Cancer Institute
Kræftens Bekæmpelse
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 3 December 2025
First Online: 30 December 2025
Declarations
:
: Approval for this study was granted by the Regional Ethics Committee of Central Denmark (journal number 1-10-72-22-13), the Danish Breast Cancer Group, and the Danish Data Protection Agency (Aarhus University number 2016-051-000001, #458), and adhered to the General Data Protection Regulation. The compilation and analysis of data in this study were conducted within the secure servers of Statistics Denmark, in accordance with Danish privacy laws.
: Not applicable.
: LJC reports personal fees from Epidemiologic Research & Methods, LLC outside of the submitted work. TLL is a member of the Amgen Methods Advisory Council, for which he receives consulting fees and travel support. This work is outside of the submitted work. BE reports outside the submitted work an Advisory Role: Eli Lilly; Research funding: Institutional grants from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, and Seagen; and Travel, Accommodations, Expenses: Daiichi Sankyo, MSD, and Pfizer. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from the European Medicines Agency and from companies in the form of research grants, unrelated to the current study. All other authors have no disclosures.
